Molecular bases determining daptomycin resistance-mediated re-sensitization to β-lactams ("see-saw effect") in MRSA by Renzoni, A.M. et al.
This is a repository copy of Molecular bases determining daptomycin resistance-mediated 
re-sensitization to β-lactams ("see-saw effect") in MRSA.




Renzoni, A.M., Kelley, W.L., Rosato, R.R. et al. (9 more authors) (2017) Molecular bases 
determining daptomycin resistance-mediated re-sensitization to β-lactams ("see-saw 






Unless indicated otherwise, fulltext items are protected by copyright with all rights reserved. The copyright 
exception in section 29 of the Copyright, Designs and Patents Act 1988 allows the making of a single copy 
solely for the purpose of non-commercial research or private study within the limits of fair dealing. The 
publisher or other rights-holder may allow further reproduction and re-use of this version - refer to the White 
Rose Research Online record for this item. Where records identify the publisher as the copyright holder, 
users can verify any specific terms of use on the publisher’s website. 
Takedown 
If you consider content in White Rose Research Online to be in breach of UK law, please notify us by 
emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request. 
1 
 
Molecular bases determining daptomycin resistance-mediated re-sensitization to く-lactams 1 
(“see-saw effect”) in MRSA  2 
 3 
Adriana M. Renzonia, William L. Kelleyb, Roberto R. Rosatoc, Maria P. Martinezc, Melanie Rochc, 4 
Maryam Fatouraeic, Daniel P. Haeusserd, William Margolind, Samuel Fenne, Robert D. Turnere, 5 
Simon J. Fostere and Adriana E. Rosatoc∗ 6 
 7 
aHopitaux Universitaires de Genève, Service of Infectious Diseases, Geneva, Switzerland 8 
bUniversity of Geneva Medical School, Department of Microbiology and Molecular Medicine, 9 
Geneva, Switzerland   10 
cDepartment of Pathology and Genomic Medicine, Center for Molecular and Translational Human 11 
Infectious Diseases Research, Houston Methodist Research Institute, Houston, TX 12 
dDepartment of Microbiology and Molecular Genetics, McGovern Medical School, University of 13 
Texas, Houston, TX 14 
eKrebs Institute, University of Sheffield, Firth Court, Western Bank, Sheffield, United Kingdom 15 
∗Corresponding author:  16 
Houston Methodist Research Institute, 6670 Bertner Ave., Room R6-113, Houston, TX 77030  17 
Phone: 713-441-4369; Fax: 713-441-2895  18 
E-mail: aerosato@HoustonMethodist.org 19 
Short title: Daptomycin/く-lactams/PrsA and MRSA  20 
Keywords: MRSA, daptomycin, see-saw effect, く-lactams, PrsA  21 
AAC Accepted Manuscript Posted Online 24 October 2016
Antimicrob. Agents Chemother. doi:10.1128/AAC.01634-16
Copyright © 2016, American Society for Microbiology. All Rights Reserved.
 on N
ovem






























   ABSTRACT 22 
Antimicrobial resistance is recognized as one of the principal threats to public health worldwide, 23 
yet the problem is increasing. Methicillin–resistant Staphylococcus aureus (MRSA) are among 24 
the most difficult to treat in clinical settings due to the resistance to nearly all available 25 
antibiotics. The cyclic anionic lipopeptide antibiotic Daptomycin (DAP) is the clinical mainstay 26 
of anti-MRSA therapy. Decreased susceptibility to DAP (DAPR) reported in MRSA is 27 
frequently accompanied with a paradoxical decrease in く-lactam resistance, a process known as 28 
the “see-saw” effect. Despite the observed discordance in resistance phenotypes, the combination 29 
of DAP/く-lactams has been proven clinically effective for the prevention and treatment of 30 
infections due to DAPR-MRSA strains. However, the mechanisms underlying the interactions 31 
between DAP and く-lactams are largely unknown. Herein, we studied the role of DAP-induced 32 
mutated mprF in く-lactam sensitization and its involvement in the effective killing by the 33 
DAP/OXA combination. DAP/OXA-mediated effects resulted in cell-wall perturbations 34 
including changes in peptidoglycan (PG) insertion, penicillin-binding protein 2 (PBP2) 35 
delocalization and reduced membrane amounts of penicillin-binding protein 2a (PBP2a) contents 36 
despite increased transcription of mecA through mec regulatory elements. We have found that the 37 
VraSR sensor-regulator is a key component of DAP resistance, triggering mutated mprF-38 
mediated cell membrane (CM) modifications and resulting in impairment of PrsA location and 39 
chaperone functions, both essentials for PBP2a maturation, the key determinant of く-lactam 40 
resistance. These observations provide first time evidence that synergistic effects between DAP 41 





































S. aureus has a proclivity for developing multidrug resistance (e.g., methicillin-resistant S. aureus, 47 
MRSA) and infections with this pathogen result in enhanced attributable mortality (33). Since its 48 
FDA approval in 2003, the cyclic anionic lipopeptide antibiotic daptomycin (DAP) produced by 49 
Streptomyces roseosporus (3), has become the clinical mainstay of anti-MRSA therapy due to its 50 
potent staphylocidal activity (1). The mechanism of action of DAP involves the disruption of 51 
cytoplasmic membrane (CM) function leading to its depolarization and causing cell death (2). 52 
However, there have been a number of reports in which initially DAP-susceptible (DAPS) MRSA 53 
strains developed DAP resistant (DAPR) phenotypes during clinical treatment failures (4,28). DAPR 54 
strains obtained from therapeutic failure are associated with a number of gene mutations linked with 55 
DAP resistance, including those in CM associated genes (e.g. mprF) and cell wall (CW) (e.g., the 56 
two-component system YycFG), and others as mutations in RNA polymerase subunits RpoB/C (16). 57 
However, the most clinically significant and relevant changes are those associated with mutations in 58 
mprF (4,28). In previous studies, we demonstrated by using sets of isogenic DAPS and DAPR 59 
strains that, in addition to mprF, resistance to DAP involved the upregulation of genes involved in 60 
CW synthesis and turnover, including the two-component regulator and CW stress stimulon vraSR 61 
(28). Together, these observations led us to postulate that both CM and CW components contribute 62 
to decreased susceptibility to DAP.  63 
Interestingly, we and others have observed both in vitro (29,38,49) and in vivo (13,29,30) that DAP 64 
resistance sensitizes MRSA to く-lactams, notably oxacillin, a process known as a “see-saw” effect 65 
(29). Indeed, we have demonstrated that combinations of DAP with OXA (in-vitro) or nafcillin 66 
(NAF) (in-vivo), as well as other く-lactams such as cefotaxime (CTX), which targets PBP2, and 67 
carbapenems, such as imipenem (IPM) that target PBP1, displayed strong synergistic interactions 68 
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against DAP resistant MRSA (29). Although the DAP/く-lactam combination is extensively used in 69 
clinical settings for the treatment of MRSA infections associated with decreased susceptibility to 70 
DAP (29), the mechanistic bases of the “see-saw” effect remain to be elucidated. 71 
The PrsA protein is required for resistance to oxacillin as well as glycopeptide antibiotics in S. 72 
aureus (21,22). In Gram-positive bacteria such as Bacillus subtilis and Listeria monocytogenes, PrsA 73 
is a membrane-anchored protein that catalyzes the post-translocational folding of exported proteins, 74 
and is essential for their stability as they cross the bacterial cell membrane-cell wall interface 75 
(34,41). In B. subtilis, PrsA is required for folding of PBPs and lateral cell wall biosynthesis; in the 76 
absence of PrsA, four PBPs (PBP2a, PBP2b, PBP3 and PBP4) become unstable (8). Additionally, in 77 
L. monocytogenes, PrsA2 contributes to bacterial pathogenesis and virulence (10).  Expression of 78 
prsA is induced upon encountering cell wall active antibiotics and induction is dependent upon the 79 
activity of VraSR, the cell wall stress two-component system (22). Importantly, the same authors 80 
reported that cells were more susceptible to oxacillin in the absence of PrsA, suggesting that PrsA 81 
may be involved in oxacillin resistance in concert with VraSR, PBP2 and PBP2a (22). Recent PrsA 82 
structure and function analyses revealed that PrsA modulates PBP2a protein levels independent of 83 
the SCCmec background strains (21). Regulation of PBP2a expression at the transcriptional level 84 
involves mecI, mecR, and blaRZ, which may vary in SCCmec types, but less is known about the 85 
post-transcriptional maturation and proper localization of PBP2A.  86 
In the present study, we demonstrate that DAPR-mediated mprF mutations result in significant 87 
changes in cell wall synthesis by influencing the function of PrsA, which correlates with reduced 88 
amounts of く-lactam-induced PBP2a. This work provides evidence that MprF and PrsA are 89 
important for the sensitization to く-lactams during DAP resistance in MRSA (see-saw effect), 90 
and contributes new insights into the mechanisms associated to this effect.  91 
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MATERIALS AND METHODS 92 
Bacterial strains, plasmids and antibiotics. All clinical strains used in this study are listed in Table 93 
1. Trypticase Soy Agar with 5% sheep blood (BBL, Sparks, MD) was used for subculture and 94 
maintenance of S. aureus. Staphylococcus aureus and E.coli were grown in Mueller-Hinton Broth 95 
(MHB). Standard reference antibiotics, tetracycline (TET, 3ug/ml), chloramphenicol (CM, 10ug/ml), 96 
oxacillin (OXA) range 0.5 to 10 µg/ml) were obtained from Sigma, St. Louis, MO; United States 97 
Biochemicals, Cleveland, OH Daptomycin (DAP) was provided by Cubist Pharmaceuticals/Merck 98 
(Lexington, MA). DAP and OXA were used at concentrations adjusted based on strains MICs in 99 
parental and genetic mutants. Calcium was added at concentration of 50 mg/L for DAP. 100 
Antimicrobial susceptibility to OXA was determined according to the guidelines of the Clinical and 101 
Laboratory Standards Institute (32). DAP MICs were determined by Etest (AB Biodisk, Solna, 102 
Sweden).  103 
Membrane protein extraction. For the isolation of membrane proteins, strains were grown in MHB 104 
until mid-exponential phase and pellets were resuspended in 600 µl of PBS. Bacterial cells were 105 
disrupted by adding glass beads and using a FastPrep cell disrupter (MP Biomedicals, Santa Ana, 106 
CA) and the lysate was centrifuged at 8,000 g for 10 min at 4°C. The supernatant fraction was 107 
centrifuged for additional 5 min at 8,000 g at 4°C to remove beads and then the supernatant was 108 
transferred to ultracentrifuge tubes and centrifuged at 45,000 rpm in a Thermo Sorvall WX ULtra 109 
Series WX80 (Thermo Scientific, Waltham, MA) for 1 h at 4°C. The membrane pellet was 110 
resuspended in PBS and total membrane proteins were quantified by Bradford protein assay 111 
(Thermo Fisher) and stored at -80°C. 112 
Secreted protein preparation. Bacteria were grown in MHB until OD600 aprox. 0.3. Then samples 113 
were centrifuged for 10 min at 4,000 rpm and the supernatant was passed through 0.22 µm 114 
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membrane filters (Millex). Samples were normalized by volume adjustment to equal sample OD and 115 
20 µg of carbonic anhydrase (Sigma) were added as an internal spike control as described (Andrey et 116 
al., 2015). Samples were concentrated in Amicon 10000MWCO centrifugal filters (Millipore) to a 117 
final volume of 40 µl. 118 
Western blotting. Proteins (15 たg) were separated on 4-12% Bis-Tris gels and blot transferred onto 119 
pure nitrocellulose blotting membranes (PALL Life Science). Membranes were blocked using 5% 120 
low-fat milk in PBS. PBP2A was probed with monoclonal anti-PBP2A antibody (Slidex MRSA 121 
Detection kit, BioMerieux, France) at a 1/2000 dilution followed by incubation with a secondary 122 
alkaline phosphatase-labeled goat anti-rabbit lgG (H+L) antibody at a 1/5000 dilution. Labelled 123 
protein signal was detected using a SRX/101A Film Processor (Konica Minolta). 124 
DNA manipulation and sequencing. Chromosomal DNA was prepared by using a Qiagen genomic 125 
DNA preparation kit (Qiagen, Inc. Valencia, CA) according to the manufacturer's directions. 126 
Sequencing of all PCR amplification products was performed at the Nucleic Acid Research Facility 127 
at GENEWIZ (South Plainfield, NJ). Sequence analysis of mprF in wild type strains and mutants 128 
was performed by using mprF primers as previously described (28). Consensus sequences were 129 
assembled from both orientations with Lasergene 12 software (DNASTAR, Madison, WI). S. aureus 130 
N315 (accession # BA000018) was used as a reference sequence control.  131 
RNA extraction and RNA-Seq. Total RNA was extracted using an RNeasy isolation kit (Qiagen). 132 
The concentration and integrity of RNA samples was assessed by A260/A280 spectrophotometry and 133 
gel electrophoresis. RNA samples were cleaned and treated with DNase following the 134 
manufacturer’s recommendations to avoid potential DNA contamination. RNA was prepared from 135 
CB1634 cells collected at exponential phase of growth at the different conditions in absence and 136 
presence of DAP, OXA and DAP/OXA.  The genome-wide transcript sequencing libraries were 137 
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prepared according the manufacturer’s instructions (ScriptSeq, EpiCentre) and sequenced on a 138 
MiSeq instrument (Illumina). Differential gene expression was determined by CLC Genomic 139 
Workbench and Lasergene software; differences >1.5 fold and P<0.05 after applying Bonferroni 140 
correction for multiple comparisons were considered significant. 141 
Analysis of gene expression by RT-PCR. Real-time reverse transcription-PCR analysis for RNA 142 
samples were done using a SensiMix SYBR One/Step kit (Qantace/Bioline, Taunton, MA) according 143 
to the manufacturer’s protocol. Gene expression was compared respect of a sample considered the 144 
reference (value = 1) using log2-(∆∆CT). The change (n-fold) in the transcript level was calculated 145 
using the following equations: ∆CT = CT(test DNA) – CT(reference cDNA), ∆∆CT = ∆CT(target gene) - ∆CT(16SrRNA) 146 
and ratio =2-∆∆CT. The quantity of cDNA for each experimental gene was normalized to the quantity 147 
of 16S cDNA in each sample. Oligonucleotide primers are shown in Table 1. 148 
Microscopy, labelling and imaging of DAPS and DAPR cells. Parental DAPS; CB1631 and 149 
resistant DAPR; CB1634 strains were grown in TSB in absence and presence of DAP (0.25 and 150 
1たg/ml, respectively) at 37°C to exponential phase, labelled for 5 min with either HADA (stains 151 
nascent peptidoglycan insertion), FM1-43FX (stains the cell membrane), DAPI (stains DNA) or 152 
vancomycin (stains nascent D-Alanyl-D-Alanine incorporation into CW) (Sigma) mixed with a 153 
BODIPY FL conjugate of vancomycin (Van-FL, Molecular Probes) to a final concentration of 0.8 154 
たg/mL. Images were obtained with a Nikon inverted epifluorescence microscope.  For localization 155 
studies of PBP2, the corresponding gene pbpB was expressed as an N-terminal GFP fusion protein in 156 
CB1634. Genomic DNA was PCR amplified using Phusion DNA polymerase and the primers pbp2-157 
0F (DPH407) and pbp2-R (DPH408) (Table 1).  PCR fragments were digested with NotI and BamHI 158 
and ligated into a cleaved pEA18 vector, in frame with gfp (originally cloned from pDSW207) to 159 
generate pDH177 in E. coli AG111 competent cells. The gfp-pbpB fragment, including the B. 160 
subtilis spoVG ribosome binding site sequence of pEA18, was subcloned from pDH177 by digestion 161 
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with HindIII and BamHI and ligated into cleaved pCL15 vector to generate pDH178. pDH178 was 162 
initially cloned into E. coli AG1111 (Promega Wizard), and transformed into S. aureus RN4220 by 163 
electroporation. The plasmid was then transduced from RN4220 into S. aureus CB1634 using phage 164 
80g. CB1634 cells containing the gfp-pbpB gene in pDH178 were induced with IPTG in the 165 
presence of OXA, DAP, or DAP/OXA to localize PBP2a during DAP/OXA synergistic effects. Cells 166 
were fixed in 2.8% formaldehyde (FA) and 0.04% glutaraldehyde (GA) in growth medium for 15 167 
min at room temperature. The cells were collected at 8000g for 5 min, washed once in PBS, treated 168 
with vectashield anti-fade reagent and visualized by fluorescence microscopy with an Olympus 169 
BX60 epifluorescence microscope containing a 100x oil immersion objective (N.A. 1.4). Images 170 
were captured with a Hamamatsu Orca charge-coupled device camera using HCImage software. 171 
Labeling of PBPs with bocillin. Bocillin labelling of 100 µg of membrane proteins was performed 172 
with 100 µM bocillin-FL (Molecular Probes) incubated for 30 min at 35°C. The reaction was 173 
stopped by adding 4xSDS-PAGE sample buffer. Labelled membrane protein concentrations were 174 
determined by Bradford protein assay and 15 たg were loaded on a 10% Bis-Tris gel and detected 175 
using a ProteinSimple Imager-FluorChem E system (GE Healthcare). 176 
Peptidoglycan purification and analysis. Exponentially growing cells (OD 600 0.5) grown on MHB 177 
untreated and treated with OXA, DAP and DAP/OXA were boiled in 4% Sodium dodecyl sulfate 178 
(SDS) and deproteinized by treatment with pronase and trypsin, then treated with 48% hydrofluoric 179 
acid (HF) at 4°C for 16hs, washed several times with 0.25M Tris-HCl and water before 180 
lyophilization. Purified peptidoglycan was digested with 25 µg/ml of mutanolysin (Sigma).  The 181 
soluble muropeptides were reduced with sodium borohydride. The reaction was stopped by the 182 
addition of phosphoric acid and the supernatant containing peptidoglycan was analyzed in a LC-183 
20AB HPLC equipped with a SPD-20A UV detector (Shimadzu). The separation of muropeptides 184 
was performed in a Jupiter Proteo column (C18, 250 x 4.6 mm, 4µm, 90A) (Phenomenex). 20 µl of 185 
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sample were eluted at 0.5 ml/min for 5 minutes with 95% A (100 mM sodium phosphate buffer pH 186 
3.0 containing 0.00025% sodium azide) and 5% B (methanol) and then B was increased up to 30 % 187 
at 120 min as previously described. (18) Detection was performed at 206 nm and peaks were 188 
identified by comparison with the elution profile for peptidoglycan from COL strain previously 189 
reported (12). 190 
Statistical analyses. Statistical tests were performed using SPSS v17.0 for Windows (SPSS Inc., 191 
Chicago, IL, USA). The survival data were plotted using the Kaplan–Meier methods. 192 
 193 
RESULTS 194 
Daptomycin-induced cytoplasmic membrane and cell wall changes. Despite considerable 195 
evidence pointing to the action of DAP on the CM, the CW has also been suspected to be an 196 
important target as recently shown in B. subtilis (17,36). We used fluorescence microscopy to 197 
visualize the effects of DAP on both CM and CW functions. When DAPS CB1631 cells were treated 198 
with DAP, they displayed significant morphological changes at the CM level (Fig. 1A, FM1-43X 199 
staining, upper panels), including shape abnormalities and size heterogeneity compared with 200 
untreated control cells (No DAP). All the cells contained DNA as judged by DAPI staining (not 201 
shown), indicating that DAP did not cause significant alterations to the nucleoid.  202 
This observation was corroborated by analysis of the pattern of nascent peptidoglycan (PG) insertion 203 
using the fluorescent D-amino acid derivative HADA (HCC-amino-D-alanine). Exposure of DAPS 204 
CB1631 to DAP induced the delocalization of PG insertion (Fig.1A, lower panels), suggesting that 205 
PBPs were displaced from the division septum, where CW synthesis normally takes place. 206 
Importantly, none of the changes described in DAPS CB1631 were observed in the DAPR CB1634 207 
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counterpart (Fig.1B, right panels). These observations are in agreement with the hypothesis that DAP 208 
induces dramatic effects on both the CM and CW in S. aureus.  209 
Effects on cell wall rearrangements during exposure to a combination of DAP and く-lactams. 210 
We previously observed that DAP-mediated sensitization to く-lactams occurred with those that 211 
preferentially target PBP1 or PBP2, including NAF (PBP1, PBP2), IPM (PBP1) and CTX (PBP2), 212 
whereas no changes were observed with β-lactams targeting PBP4 such as cefoxitin (FOX) or PBP3  213 
such as cefaclor (CEC) (6,7,29). Similar effects were observed in other in vitro-selected DAPR 214 
mutants obtained from DAPS CB1631 (DAPR-CB1631) and CB5011 (DAPR-CB5011) (29). 215 
Collectively, these observations suggest that the see-saw effect involves CW modifications.  216 
To address this in more detail, we stained cells with BodipyFL-VAN, which has been used extensively 217 
to detect the localization of newly synthesized peptidoglycan in Gram-positive bacteria (47,48). DAPR 218 
CB1634 cells were grown without/with DAP/OXA combination followed by BodipyFL-VAN staining 219 
(10 min) and detection by fluorescence microscopy (Fig. 2). In the untreated control BodipyFL-VAN 220 
intensely stained the complete equatorial cell septa and faintly the side-walls; in contrast, cells grown 221 
in the presence of DAP/OXA showed mostly delocalized BodipyFL-VAN staining (Fig. 2A). These 222 
results are consistent with the delocalized peptidoglycan insertion patterns by HADA staining (Fig. 1), 223 
and suggest that co-administration of DAP with く-lactams causes dramatic local effects on the CW in 224 
DAPR cells similar to those observed in DAPS cells (CB1631) such as displacement of PBPs from the 225 
septum). In fact, studies of the labeling of newly synthesized CW with fluorescein-conjugated VAN in 226 
S. aureus have suggested that most CW synthesis is confined to the division septum, where both PBP1 227 
and PBP2 are localized (35).  228 
To investigate further the hypothesis that the combined CW effects of DAP and く-lactams contribute to 229 
the delocalization of PBPs, particularly PBP1 and PBP2, we generated a CB1634-derivative strain 230 
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expressing an IPTG-regulated PBP2-GFP fusion protein. The CB1634-PBP2-GFP strain, untreated 231 
cells showed that PBP2-GFP protein clearly localized to the equatorial cell septa (Fig. 2B). In contrast, 232 
exposure to a DAP/OXA combination resulted in diffused and delocalized distribution of PBP2-GFP, 233 
in agreement with the results in Fig. 2A. Similar observations were made by using the same approach 234 
with a PBP1-GFP fusion protein (data not shown). We next wanted to determine the activity of PBPs 235 
by measuring their binding affinity to a fluorescent く-lactam, Bocillin FL. The DAPR CB1634 strain 236 
was exposed to DAP (1µg/ml), OXA (0.5µg/ml) and DAP/OXA (1µg/ml/0.5µg/ml, respectively), 237 
and PBPs separated by SDS-PAGE were analyzed for their ability to bind Bocillin FL.  As shown in 238 
Fig. 3, DAPR CB1634 cells treated with DAP/OXA and subsequently labelled with bocillin 239 
displayed a decreased levels of PBP1, PBP2 and PBP3, whereas no changes were observed with 240 
either DAP and/or OXA alone. However, since we have previously shown that inhibition of PBP3 by 241 
CEC did not result in see-saw effect when combined with DAP (29), the present results may indicate 242 
that PBP1 and PBP2 have a relevant role in the DAP-associated see-saw effect and restoration of 243 
susceptibility to く-lactams in (MRSA) DAPR strains.  244 
 245 
Sensitization to β-lactams during DAP resistance is associated with decreased production of 246 
PBP2a.  く-lactam resistance in MRSA involves the horizontal acquisition of the mecA gene, which 247 
encodes PBP2a, a PBP with low affinity for く-lactams that can mediate cell wall assembly when the 248 
normal staphylococcal PBPs (PBP1 to 4) are inactivated by these agents (35). To determine a 249 
potential role for PBP2a in the DAP-mediated see-saw effect observed in DAPR strains, PBP2a 250 
protein expression levels were analyzed by western blotting using cell membrane protein extracts 251 
prepared from CB1634 treated with OXA, DAP and the DAP/OXA combination. Compared to 252 
untreated control cells, no PBP2a induction was observed with DAP, while as expected, the levels of 253 
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PBP2a increased significantly after exposure to OXA (Fig. 4A). Importantly, in DAP/OXA-treated 254 
CB1634 cells there was a marked reduction in PBP2a levels when compared to OXA induction. 255 
Analysis of OD600-normalized extracellular extracts showed increased amounts of extracellular 256 
PBP2a in the corresponding CB1634 treated with DAP/OXA  strain while no extracellular PBP2a 257 
was detected in extracts from collected from the control untreated sample (Fig. 4A). A slight 258 
increase on the extracellular amounts of PBP2a was also observed in extracts from OXA-treated 259 
cells, consistent with increasing amounts of cell membrane-associated protein. These results strongly 260 
suggest that PBP2a localization to the CM is altered, which in turn would be associated with the 261 
DAPR phenotype mediated see-saw effect. 262 
To determine whether reduction of PBP2a levels observed with the DAP/OXA combination was 263 
linked to alterations in mecA transcriptional regulation, we evaluated mecA mRNA levels in the 264 
absence and presence of DAP, OXA and DAP/OXA by real-time RT-PCR analysis. We found that 265 
mecA transcription in the CB1634 strain displayed significant induction by OXA alone, an effect that 266 
was further enhanced in the case of OXA/DAP (Fig. 4B); a modest induction was also observed 267 
upon exposure to DAP. These results do not correlate with the changes in CM-associated PBP2a 268 
protein levels subject to the various drug combinations, and thus cannot be attributed solely to 269 
changes in the transcription of the mecA gene.  Furthermore, the results strongly suggest that these 270 
alterations during the see-saw effect may critically interfere with the normal synthesis/function of 271 
the CW.  272 
We next wanted to establish whether DAP-induced mutations in mprF, which potentially are 273 
associated with changes in the CM, may play a role in PBP2a and CW changes observed during the 274 
see-saw effect. To address this, we analyzed PBP2a protein levels using membrane protein extracts 275 
from DAPR-CB1634, CB1634∆mprF, and CB1634∆mprF complemented either with WT-mprF or a 276 
previously isolated mprF mutant (mprFL826F) that is associated with decreased susceptibility to 277 
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DAP (28). As depicted in Fig. 4C, cellular levels of membrane-associated PBP2a were sharply 278 
increased by exposure to OXA in all strains compared to either the corresponding untreated controls 279 
or DAP-treated cells. Importantly, the strong reduction of PBP2a levels in the parental CB1634 280 
strain exposed to DAP/OXA (Fig. 4A) was not observed in the CB1634∆mprF strain MAR17 (Fig. 281 
4C). Interestingly, complementation of MAR17 with WT-mprF (MAR18 strain) resulted in the same 282 
PBP2a profile detected in MAR17, indicating that there were no differences in the amount of CM-283 
associated protein between OXA- and DAP/OXA-treated cells. However, PBP2a levels were 284 
significantly reduced in CB1634∆mprF complemented with mprFL826F (strain MAR19), following 285 
the same pattern observed in the parental CB1634 displaying the see-saw effect.  These results 286 
indicate that DAP-mediated changes in mprF and/or the CM associated with the DAPR phenotype 287 
alter the membrane levels of PBP2a and thereby may interfere with the normal synthesis/function of 288 
the CW.  289 
Functional role of mprF mutations on peptidoglycan cross-linking and DAP availability during 290 
DAPR and the see-saw effect. Given the effects of altered MprF on PBP2a levels, we next wanted to 291 
determine the influence of mprF mutations on the DAP-mediated “see-saw” effect. Phenotypic 292 
analysis comparing DAPR CB1634 vs. its CB1634〉mprF counterpart showed that inactivation of 293 
mprF led to increased susceptibility to DAP (MIC DAP: 4 µl/ml vs. 0.25 µl/ml, respectively), and 294 
increased resistance to OXA (MIC OXA: 0.5 µl/ml vs. 32 µl/ml, respectively; Table 2). Importantly, 295 
complementation of CB1634〉mprF with WT mprF did not revert the phenotype (DAP or OXA 296 
MIC: 0.75 µg/ml vs. 32 µg/ml, respectively). In contrast, complementation with mprFL826F 297 
restored the resistance to DAP (MIC = 3 µg/ml) and decreased resistance to OXA (MIC = 1 µg/ml), 298 
re-establishing the DAP-mediated “see-saw” effect (Table 2). Similar results were observed with the 299 
DAPS/R pair CB5011/CB5012-(mprFL826F) (data not shown). 300 
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We next determined the impact of mprF mutations and the implications of altered levels of PBP2a 301 
on the CW during the DAP-mediated see-saw effect. The muropeptide composition of peptidoglycan 302 
was measured in DAPR CB1634 cells untreated and treated with DAP/OXA after separation by 303 
reverse phase HPLC. Analysis of the HPLC profiles revealed marked differences in CW cross-304 
linking in CB1634 ± DAP/OXA (Fig. 5A), showing that exposure to DAP/OXA resulted in a 305 
significant decrease in the amount of highly cross-linked oligomer muropeptides (peaks # 17-22), 306 
which should reduce CW rigidity. These results are in accordance with our data showing that 307 
exposure of DAPR strains to DAP/OXA reduces the levels of PBP2a associated with the CM, which 308 
in turn could lead to the observed CW rearrangements and increased oxacillin susceptibility. 309 
To investigate the role of mprF in CW composition, notably taking into account the observations 310 
described above, we compared muropeptide profiles of CB1634 with those of the CB1634 ΔmprF 311 
mutant. While no differences in profiles were observed between both strains in the absence of 312 
antibiotics (Fig. 5B, upper panels), the addition of OXA in the CB1634-〉mprF strain, showed 313 
significantly enrichment for monomeric and dimeric components. These mprF-dependent effects 314 
were further enhanced by co-exposure to DAP/OXA (Fig. 5B, middle and lower panels, 315 
respectively), providing a plausible explanation for the ability of the mprF deletion in DAPR strains 316 
to reverse the increased susceptibility to OXA during the see-saw effect, as shown in Table 2.  317 
Crosstalk between MprF and PrsA proteins. To understand further the molecular mechanism 318 
linking the mprFL826F mutation with decreased PBP2a levels in the CM and PG crosslinking 319 
during the see-saw effect, three basic observations were important to consider. First, we recently 320 
demonstrated that PrsA, a lipoprotein acting as a post-translocational chaperone, is involved in く-321 
lactam resistance by affecting amounts of PBP2a in the CM (20); in addition, prsA expression is 322 
regulated by the two-component system VraSR (22). Second, we have shown that acquisition of 323 
DAPR involves upregulation of genes controlling CW synthesis and turnover, including vraSR (28).  324 
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Unpublished RNA-Seq results suggest that vraSR and prsA genes in the DAPR CB1634 strain are 325 
up-regulated compared to the DAPS CB1631 strain, suggesting a link between the mprF (L826F) 326 
mutation present in CB1634 and changes in the expression of both vraSR and prsA genes. Third, 327 
MprF has been shown to be involved in the modification of the membrane phospholipid 328 
phosphatidylglycerol, which in turn acts as a substrate for the Lgt enzyme that modifies lipoproteins 329 
such as PrsA (46).  330 
In light of these observations, we hypothesized that DAPR-associated mprF mutations could affect 331 
the ability of PrsA to associate with the CM and consequently affect its functional activity. To test 332 
whether PrsA and MprF are mutually interconnected during the DAPR-mediated see-saw effect, we 333 
first evaluated cellular levels of PrsA and its localization in both CM and extracellular protein 334 
extracts (Fig. 6). Consistent with the RNA-Seq analysis, we observed that steady state levels of PrsA 335 
in the CM were higher in CB1634 vs. CB1631 (Fig. 6A). Interestingly, levels of PrsA, almost 336 
undetectable in the absence of mprF (CB1634∆mprF), were restored by complementation with 337 
mprFL826F (CB1634∆mprF+ mprFL826F), but not by WT mprF (CB1634∆mprF+mprF) (Fig. 338 
6A). Concomitant analysis of OD600-normalized extracellular extracts showed increased amounts of 339 
extracellular PrsA in the corresponding CB1634∆mprF and CB1634∆mprF+mprF (WT) strains, 340 
while no extracellular PrsA was detected in extracts from the CB1634∆mprF+mprFL826F strain 341 
(Fig. 6A). These results strongly suggest that PrsA localization to the CM is altered by the mprF 342 
mutation, and this in turn is associated with the DAPR phenotype. 343 
PrsA-mediated effects on CM-associated PBP2a are triggered by the mprFL826F mutation. 344 
Since DAP-mediated effects during the see-saw effect involve alterations in PBP2a levels in the 345 
membrane (Fig. 4A) and taking into account the PrsA-mediated regulatory role in く-lactam 346 
resistance via modulation of PBP2a (21), we hypothesized that during acquisition of DAPR, cell 347 
membrane modifications triggered by mutations in mprF alter PrsA membrane localization and 348 
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consequently PBP2a membrane levels. To test this idea, we measured PBP2a and PrsA protein levels 349 
in CM extracts prepared from CB1634 (carrying mprFL826F) grown in the absence or presence of 350 
DAP, OXA and the DAP/OXA combination. As shown in the Western blot in Fig. 6B, PBP2a and 351 
PrsA membrane protein levels were induced upon OXA stress, but consistent with our hypothesis, 352 
the DAP/OXA combination resulted in decreased cell membrane levels of PBP2a that correlated 353 
with a concomitant reduction of PrsA. Taken together, our results strongly suggest that despite 354 
DAP/OXA-induced transcriptional up-regulation of mecA, mprF-dependent loss of CM-anchored 355 
PrsA results in depletion of PBP2a. Thus, the acquisition of DAPR via an mprF-dependent 356 
mechanism results in insufficient levels of PBP2a needed to sustain resistance to く-lactams, an effect 357 
mediated by altered cell membrane localization of PrsA. 358 
Homogeneous DAPR MRSA strains do not display the see-saw effect without DAP induction. 359 
In previous studies, we reported that two DAPR strains, CB5036 and CB5014 with mutations at 360 
MprF located at the central domain, P314L and S377L respectively, did not display the DAP-361 
mediated see-saw effect, i.e. their OXA MICs remained the same (512 µg/ml) in both DAPS/R 362 
paired strains (CB5035/CB5036 and CB5013/CB5014, respectively (29). However, as we described, 363 
the DAP/OXA combination was still effective against them (29). These strains are called 364 
homogeneous MRSA because they express a uniformly high level of く-lactam resistance, different 365 
from the heterogeneous MRSA strains (e.g., CB1634) whose cell populations are able to express 366 
differential levels of resistance and that are mostly associated with lower MICs (1-32 µg/ml).  367 
We hypothesized that the absence of DAP selection prevented detection of the see-saw effect in 368 
these strains. We tested this idea by growing cultures of DAPR strain CB5014 in the presence of sub 369 
lethal (½ MIC) concentrations of DAP (2 µg/ml DAP, 50 mg/L Ca2+), after which the adjusted 370 
inoculum was plated onto MH agar containing ½ MIC of DAP (2 µg/ml). OXA E-test strips were 371 
placed on the plates and incubated for 24 h, after which a pronounced decrease in the OXA MIC 372 
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from 512 µg/ml to 1 µg/ml was observed (Fig. 7A-B); this low-level DAP-induced strain will be 373 
referred as CB5014IndD. Similar results were obtained with DAPR strain CB5036 (data not shown). 374 
In support of these observations, PBP2a was detectable in membrane extracts from CB5014 grown 375 
O/N without DAP induction and then exposed to DAP/OXA, whereas in CB5014IndD under the 376 
same conditions, levels of the protein became almost undetectable (Fig. 7C). These results are 377 
consistent with the appearance of the DAP-mediated see-saw effect, as it was only displayed in the 378 
CB5014IndD strain. Furthermore, as previously shown for CB1634 (Fig.4A), the absence of PBP2a 379 
in cell membrane extracts collected from CB5014IndD was not related to a decrease in the 380 
transcription levels of mecA mRNA: in the presence of OXA, either alone or in combination with 381 
DAP, mecA expression was highly induced (~4-5.6 fold, respectively; Fig. 7D). CB5014 exposed to 382 
OXA or OXA/DAP also showed increased mecA expression, although to lower levels than those 383 
observed in CB5014IndD (Fig. 7D). Together, these data suggest that DAPR homogeneous MRSA 384 
relies upon DAP induction-mediated factors to express the see-saw phenotype.  385 
Role of VraSR in the DAP-mediated see-saw effect. As mentioned, we previously demonstrated 386 
the critical role played by the VraSR two-component regulatory system in the acquisition of DAPR 387 
(36)  Moreover, DAPR strains including the homogenous CB5014 and CB5035 expressed higher 388 
levels of vraSR than their corresponding DAPS counterparts (36). To further elucidate and 389 
understand the mechanistic role of DAP-induced vraSR expression and the see-saw effect, we 390 
overexpressed vraSR in the corresponding DAPS CB5013 (OXA MIC= 512 µg/ml) and CB1631 391 
(OXA MIC= 32 µg/ml) strains.  This resulted in vraSR expression levels similar to those observed in 392 
the corresponding DAPR counterparts CB5014 and CB1634, as determined by RT-PCR (data not 393 
shown). Phenotypic analyses performed by OXA E-test showed that CB5013+vraSR and 394 
CB1631+vraSR displayed both DAP-mediated see-saw effects, i.e. decreased DAP susceptibility 395 
(MICs to DAP:  4 µg/ml) and oxacillin resistance (MICs to OXA: 0.25/0.5 たg/ml, DS 396 
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CB5013+vraSR and CB1631+vraSR, respectively; Fig.8A). Moreover, analysis of mprF DNA 397 
sequences in these strains revealed amino acid changes that were identical to those present in their 398 
DAPR counterparts (S337L in CB5014 and L826F in CB1634), demonstrating that DAP-mediated 399 
increased expression of vraSR leads to polymorphisms in mprF.  To investigate further the potential 400 
role of DAP-mediated increased vraSR expression in changes in antibiotic susceptibilities related to 401 
the see-saw effect, we analyzed PBP2a levels in cell membrane lysates from CB5013+vraSR and 402 
CB1631+vraSR overexpression strains. As depicted in Fig. 8B, increased PBP2a levels were 403 
observed at baseline in CB5013+vraSR compared to those in the other strains. When exposed to 404 
OXA alone, all strains showed increased amounts of cell membrane-associated PBP2a.  Importantly 405 
however, membrane-associated PBP2a was undetectable following exposure to DAP/OXA in both 406 
strains expressing higher levels of vraSR, consistent with the see-saw effect described above.  407 
To gain further insights on potential differences between the strains displaying see-saw effect, i.e. 408 
CB1634 and CB5014IndD, we compared the overall gene expression profile by comparing RNA-409 
Seq data after exposure to OXA or DAP/OXA. Expression of approximately 322 genes was 410 
significant altered (p<0.05 and over two-fold difference; Supplemental Table 1). Of these, relevant 411 
observations comparing CB5014IndD (DAP/OXA) vs CB1634 (DAP/OXA) included upregulation 412 
of vraSR mRNA levels (~6-folds), accompanied by increased expression of vraSR target genes 413 
transcripts pbp2 (~4 folds) and sgtB (~3.5folds). In addition, mecA mRNA was also highly 414 
upregulated (~21 and 5 folds, DAP/OXA – OXA, respectively), as well as mecI/mecRI (~5 and 3 415 
folds. Other genes included those coding for proteins involved in the synthesis of PG precursors 416 
(murA-G, femAB, mraW, between 6 and 3.9 folds) while downregulated genes were associated to 417 
other gene class families,  i.e. biosynthesis and metabolic pathways as iron (fer, fmhA) and histidine 418 
(hisG, hisH), gluconate (gntP/gntK). Together, these results provide strong evidence supporting the 419 
key mechanistic role played by increased expression of vraSR following DAP exposure and its 420 
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implication in the process leading to acquisition of DAP resistance and the concomitant see-saw 421 
effect.  422 
DISCUSSION 423 
DAP targets the bacterial CM, causing rapid membrane depolarization and cell death (3). Decreased 424 
susceptibility to DAP in S. aureus has been reported leading to clinical failures in patients with 425 
MRSA deep side infections such as endocarditis and abscesses (14,23,25). Previously, we identified 426 
two major factors to mutually cooperate with acquisition of DAP resistance, one related to the cell 427 
membrane (mrpF mutations) and the second affecting cell wall factors (VraSR) (28). Moreover, we 428 
observed that the DAPR phenotype was accompanied with increased susceptibility to OXA, the so-429 
called “see-saw” effect. Previously, a concomitant rise of vancomycin resistance with decreased β-430 
lactams resistance has been reported in some clinical vancomycin intermediate S. aureus (VISA) and 431 
Vancomycin Resistant S. aureus (VRSA). In VISA strains the mechanism remains undefined with 432 
some strains showing excision of SCC mec carrying mecA, while in others mecA is retained (44,45). 433 
By contrast in VRSA strains loss of β-lactam resistance seems to be associated with the inability of 434 
PBP2a to utilize UDP-MurNAc-depsipetide (D-Ala-D-Lac) cell wall precursor produced in VRSA for 435 
transpeptidation, leaving PBP2 as essential for the synthesis of the abnormally structured cell wall 436 
(43). To date, the precise mechanism responsible for the see-saw effect mediated by DAP resistance 437 
in MRSA still remains to be elucidated.  438 
Based on the present study, we postulate that DAP-induced mprF mutations at the CM level cause 439 
alterations that affect the localization and functions of important proteins involved in cell wall 440 
construction. In this context, it has been previously noted that sub-inhibitory concentrations of DAP 441 
induce aberrant and asymmetric division septa in B. subtilis (36), reinforcing the notion that DAP 442 
may target both the CM and CW. Working on the hypothesis that by targeting the CM, DAP perturbs 443 
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the lipid environment of membrane-bound enzymes involved in PG synthesis, moderately disrupting 444 
CW assembly, we found that exposure of DAPR cells to a combination of DAP and β-lactams led to 445 
delocalization of PG synthesis from the division septum, redistributing this activity around the cell 446 
wall. We and others have observed that the “see-saw” effect is mainly achieved by く-lactams 447 
targeting PBP1 and/or PBP2 that localize at the septum of S. aureus, and furthermore, that this effect 448 
does not depend on other PG synthesis enzymes (39). Recently, it has been demonstrated that PG 449 
synthesis in S. aureus can rely solely on PBP1 and PBP2 after removing seven of the nine PG 450 
synthesis proteins (39).  The observation that only β-lactams targeting PBP1 or PBP2 are capable of 451 
killing cells during exposure to DAP/OXA supports the idea that perturbations to these proteins are 452 
largely sufficient for the MRSA sensitization observed during the see-saw effect.   453 
Importantly, we found that sensitization to β-lactams in DAPR strains containing mutant mprF alleles 454 
was associated with decreased levels of cell membrane-associated PBP2a. MprF is involved in the 455 
modification of phosphatidylglycerol, which acts as a substrate for Lgt to modify lipoproteins such as 456 
PrsA with lipid moieties (46). The present evidence highlights potential mutual interactions between 457 
MprF and PrsA during DAP-R. In fact, it is plausible to postulate that cell membrane modifications 458 
triggered by DAPR-mediated mutated MprF may affect both PrsA location and chaperone functions 459 
which are required for PBP2a folding. In support of the importance of post-transcriptional regulation, 460 
we observed, despite increased transcription of mecA through mec regulatory elements, reduced 461 
amounts of cell membrane-associated PBP2a in DAP/OXA treated cells. These findings are in 462 
agreement with recent observations by Jousselin et al. suggesting that PBP2a is a related substrate of 463 
PrsA (21), although we cannot rule out the possibility that PrsA may also influence the septal 464 
localization of PBPs, specifically PBP1 and PBP2, which are associated with the “see-saw” effect 465 
and are PrsA substrates in three Gram-positive pathogens (10).  466 
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We have previously established a role for the lipoprotein PrsA as an important mediator of both 467 
glycopeptide and oxacillin resistance, the latter through its effect on potential proper maturation of 468 
PBP2a (21,22). A consideration of MprF and the biosynthesis of lipoproteins such as PrsA suggests 469 
a plausible model to explain the see-saw effect linking DAP non-susceptibility and decreased 470 
resistance to certain antistaphylococcal Ⱦ-lactams in MRSA strains (Fig. 9). 471 
The integral membrane protein MprF uses cytosolic charged lysyl tRNA to lysinylate 472 
phosphatidylglycerol and subsequently flips lysyl phosphatidyl glycerol (L-PG) to the outer leaflet 473 
of the cytoplasmic membrane. Mutated MprF, showing enhanced enzymatic transferase and/or 474 
flippase activity, results in a significantly increased proportion of L-PG in the membrane compared 475 
to PG as well as the generation of membrane L-PG asymmetry by the selective accumulation of L-476 
PG in the outer leaflet (5,24). 477 
Prelipoproteins mature sequentially by secretion, lipidation of the lipobox cysteine embedded within 478 
the signal sequence by phosphatidylglycerol and Lgt acyl transferase, and finally signal sequence 479 
cleavage by Lsp (19,42). The study of LgtA in E. coli demonstrated that the S. aureus enzyme could 480 
fully compensate for the E. coli enzyme (37). Further high resolution X-ray structure and function 481 
analysis of the E. coli enzyme revealed mechanistic features consistent with an active site facing the 482 
periplasm and acquisition of phosphatidylglycerol substrate from the outer membrane leaflet (26). 483 
Phosphatidylglycerol is used as a substrate lipid by at least four enzymes: MprF, LtsA, Cls1/2, and 484 
Lgt to control the biosynthesis of L-PG, polymerization of lipoteichoic acid glycerol phosphate, 485 
cardiolipin, and lipidation of lipoproteins, respectively. Only LtsA is essential, indicating that the 486 
activites provided by the other enzymes using phosphatidylglycerol as a substrate are facultative. 487 
(24,46). Since LtsA governs an essential process mediating the production of lipoteichoic acid, it is 488 
reasonable to ask what permits lipobox lipidation to continue, if at all, in DAPR strains arising from 489 
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mutated MprF (or enhanced GraRS activity driving MprF production) as lysyl-PG accumulates and 490 
phosphatidylglycerol diminishes in the outer membrane leaflet.  491 
We hypothesize that disruption of lipoprotein anchorage by inhibition of Lgt-mediated acyl transfer 492 
contributes to the see-saw mechanism. Our model predicts that proper function of PrsA in particular 493 
is disrupted, and is in accordance with our experimental findings. Failure to produce sufficient 494 
lipidated PrsA would impair PrsA-dependent post-translational maturation of PBP2a, allowing 495 
transpeptidase activity to be susceptible to Ⱦ-lactams. Of course we cannot exclude alternative 496 
scenarios in which other lipoproteins such as DsbA could affect protein function (15), or the effects 497 
of membrane electrostatic charge on membrane-associated sensory processes that regulate cell wall 498 
biosynthesis (20). In support of the specific role of PrsA, we have produced a PrsA lipobox cysteine 499 
mutant that we cannot detect in membrane extracts by western blot analysis, suggesting that it is 500 
unstable and degraded, or fails to anchor and is lost (Joussselin, Renzoni, unpublished). 501 
The intriguing observation that some DAPR strains do not display a see-saw effect unless they are 502 
pre-induced with sub-lethal levels of DAP prompted us to investigate in more detail the role of 503 
VraSR.  Indeed, we found that overproduction of VraSR in DAPS strains decreased susceptibility 504 
to DAP and increased susceptibility to く-lactams, similar to made with LiaFSR, a pivotal regulator 505 
of DAPR in enterococci (11). In the absence of DAP, the three-component regulatory system 506 
LiaFSR is turned ‘OFF’ by the negative interaction of LiaF with LiaS. LiaS responds to membrane 507 
stress by phosphorylating LiaR, which leads to changes in the transcription of several downstream 508 
operons that affect CM homeostasis (11).  Interestingly, in enterococci it has been also 509 
demonstrated the ability of several く-lactams, especially ampicillin (AMP); ceftaroline (CPT) and 510 
ertapenem (ERT), in providing synergistic activity with DAP and preventing the emergence of 511 
DAP non susceptibility (31,40).  512 
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In S. aureus, VraS belongs to a subfamily of kinases that sense cell envelope stress and do not 513 
contain extracellular sensor domains (27). Although the transmembrane helices of this subgroup 514 
have been proposed to be involved in stress sensing, the precise mechanism of VraS-like kinase 515 
activation remains unknown. We propose that exposure of DAP-R strains to DAP/OXA determines 516 
membrane structure reorganization by changes in phospholipid composition which may activate 517 
VraSR signaling by promoting VraS dimerization and downstream events including 518 
autophosphorylation of VraS, phosphorylation of VraR, and gene regulation. Based on our 519 
observations, we postulate that DAP induction as seen in the CB5014IndD strain may favor 520 
oligomerization of VraR, which in turn may form a constitutively activated tetramer with high 521 
affinity for DNA, even in the absence of phosphorylation, favoring the development of DAP 522 
resistance and the see-saw effect phenotype, as in heterogeneous DAPR CB1634. We are currently 523 
studying differences in VraR oligomerization among DAP-R clinical strains that may explain the 524 
differences between heterogeneous and homogeneous DAPR –MRSA.  525 
In summary, the present study addresses the mechanistic bases and significance of sensitization to く-526 
lactams linked to DAPR in clinical MRSA strains. The combination of DAP and く-lactams has 527 
gained increased acceptance for the treatment of MRSA infections produced by DAPR strains, 528 
resulting in clinical successes. We demonstrate that VraSR is a key determinant of DAP resistance, 529 
leading to mutations in mprF that may impair PrsA chaperone functions, which are required for post-530 
transcriptional maturation of PBP2a; these effects may account for re-sensitization of DAPR strains 531 
to cell wall-specific く-lactams. Continued progress in understanding DAP’s mode of action and its 532 
impact on CM/CW machinery will provide fundamental insights into MRSA biology and be 533 
potentially translated into the discovery of new therapeutic targets.  534 
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LEGENDS TO FIGURES 731 
Fig 1. Effects of DAP on cytoplasmic membrane and cell wall of A) DAPS CB1631 or B) DAPR 732 
CB1634 bacterial strains. Bacteria were grown in TSB (±DAP) at 37 ˚C to late exponential phase 733 
(2.5 hours) and labelled for 5 minutes with FM1-43FX (membrane; upper panels), bocillin-734 
vancomycin (D-alanyl-D-alanine, cell division; middle panels) and HADA (peptidoglycan insertion; 735 
lower panels). A Nikon inverted epifluorescence microscope was used. Exposure and contrast 736 
settings were optimised per image, i.e. brightness is not comparable between fields). 737 
Fig. 2. Localization of PBP2-GFP fusions in DAPR cells treated with OXA, DAP, or 738 
DAP/OXA.  A) The DAPR-CB1634 strain producing PBP2-GFP was grown ± sublethal 739 
concentrations of DAP/OXA (1/2 MIC), followed by labelling with BodipyFL-VAN, fixation, and 740 
imaging by fluorescence microscopy. B) DAPR-CB1634 cells producing PBP2a-GFP were induced 741 
with IPTG in the presence or absence of DAP, OXA or the DAP/OXA combination, fixed, and 742 
imaged by fluorescence microscopy.  743 
Fig. 3.  Analysis of PBPs from CB1634 cells treated with OXA, DAP or DAP/OXA.  Detection 744 
of penicillin binding proteins PBP1, PBP2, PBP3 and PBP4 in membrane preparations obtained from 745 
CB1634 cells untreated and treated with OXA ( 0.5µg/ml), DAP (1µg /ml) and DAP /OXA (0.5 746 
µg/ml /1 µg/ml). Equal amounts (20 たg) of Bocillin-FL labelled membrane proteins were separated 747 
by 10% SDS-PAGE. Fluorescently labelled PBPs are indicated by arrows. 748 
Fig 4. Sensitization to β-lactams during DAP resistance is associated with decreased 749 
production of PBP2a.  A) Western blot analysis of PBP2a protein in membrane and extracellular 750 
protein extracts from DAPR-CB1634 grown without (C = control) or with DAP, OXA or DAP/OXA 751 
combination. Carbonic anhydrase was used a loading control.  B) RT-PCR analysis showing mecA 752 
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gene expression in DAPR-CB1634 grown without or with DAP, OXA or DAP/OXA combination; *: 753 
significantly higher than CB1634 control (no antibiotic), p< 0.05; # significantly higher than cells 754 
exposed to DAP or OXA alone, p< 0.05. C) Western blot analysis of PBP2a protein in membrane 755 
protein extracts from CB1643〉mprF (MAR17), CB1634〉mprF+mprF(WT)(MAR18) and 756 
CB1634〉mprF+mprFL826F (MAR19) grown without (C) or with DAP, OXA or DAP/OXA 757 
combination. 758 
FIG 5 (A) Effect of DAP/OXA combination on peptidoglycan crosslinking. Peptidoglycan 759 
muropeptide composition was analyzed by reverse phase HPLC from DAPR-CB1634 strains grown 760 
without or with DAP/OXA combination. Peaks numbered 17-22 denote highly cross-linked oligomer 761 
muropeptides. (B) Effect of mprF deletion on peptidoglycan crosslinking in presence of OXA or 762 
DAP/OXA combination. Peptidoglycan muropeptide composition was analyzed by reverse phase 763 
HPLC from DAPR-CB1634 (left panels) and DAPS-CB1634〉mprF (right panels) strains grown 764 
without or with OXA or DAP/OXA combination. 765 
FIG 6 Effect of mprF mutations on PrsA membrane localization. (A) Western blot analysis of PrsA 766 
protein in membrane protein extracts (upper panel) and extracellular protein extracts (lower panel) 767 
from DAPS-CB1631, DAPR-CB1634, CB1643〉mprF, CB1634〉mprF+mprF(WT) and 768 
CB1634〉mprF+mprFL826F grown without antibiotics. Carbonic anhydrase was used a loading 769 
control. (B) Western Blot analysis of PBP2a and PrsA in membrane extracts and from DAPR-770 
CB1634 grown without (C = control) or with OXA, DAP or DAP/OXA combination. 771 
FIG 7 Homogeneous DAPR MRSA strains do not display the see-saw effect without DAP 772 
induction. DAPR strain CB5014 grown overnight (O/N) in the absence (A) and in the presence (B), 773 
CB5014indD) of sublethal concentrations of DAP (½ MIC; 2µg/ml 50 mg/L Ca2), after which the 774 
adjusted inoculum was plated onto MH agar containing ½ MICs DAP (2 µg/ml). OXA E-test strips 775 
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were placed on the plates, and incubated for 24 h. (C) Western blot analysis of PBP2a present in cell 776 
membrane extracts collected from cells as described in (A). (D) Quantitation of mecA mRNA by 777 
real-time RT-PCR using RNA prepared from CB5014 and CB5014IndD; relative fold changes are 778 
shown; 16S rRNA: internal control. #/*: significantly higher than Control, P<0.05/0.01, respectively.  779 
FIG 8 VraSR and DAP-mediated see-saw effect. (A) CB5013+vraSR and CB1631+vraSR strains 780 
were grown O/N after which the adjusted inoculum was plated onto MH agar and OXA Etest strips 781 
were placed on the plates, and incubated at 37°C for 24 h. (B) western blot analysis of PBP2a present 782 
in cell membrane extracts collected under the indicated conditions in DAPS CB5013 and CB1631, 783 
and their corresponding +vraSR counterparts (CB5013+vraSR and CB1631+vraSR, respectively).  784 
FIG 9. Proposed model of MprF (A) or mutated MprF* (B) affecting lipoprotein PrsA anchorage. 1. 785 
MprF uses cytosolic lysyl tRNA to convert phosphatidyl glycerol (PG) to lysyl phosphatidyl 786 
glycerol (L-PG). 1b. Enhanced transferase and/or flippase activity of mutated MprF increases the 787 
proportion of L-PG compared to PG in the outer membraned leaflet. 2. Prelipoprotein PrsA is 788 
secreted probably through Sec pathway. 3. PG is used by Lgt enzyme to lipid-modify the PrsA 789 
lipobox cysteine. 3b. Inhibition of Lgt-mediated acyl transfer to PrsA due to increased L-PG/reduced 790 
phosphatidylglycerol amounts in the outer membrane leaflet. 4. Lipidated membrane-anchored PrsA 791 
will help post-translational maturation of PBP2A. 4b. Failure to produce lipidated membrane-792 






































Table 1. Strains and plasmids used in this study 799 
Strain or plasmid Description Reference 




Daptomycin resistant isogenic to CB5011; mprF L826F 
Daptomycin susceptible 




CB1631 Daptomycin susceptible      (28) 
CB1634 Daptomycin resistant isogenic to CB1631; mprf L826F      (28) 
MAR-17 CB1634 ∆mprF::cat (28) 
MAR-18 MAR-17 + pMPRF-1 (wild type)  (28) 
MAR-19 
5013 +VraSR   
1631 +VraSR 
MAR-17 + pMPRF-2 (L826F mutant) 
Entire vraS/vraR cloned into pAW8                                   






Primers and probes 
PrsA-F AGTTAATGATAAGAAGATTGACGA  
PrsA-R GAAGGGCCTTTTCAAATTTATCTTT  
VraSR-F GGTGCAACGTTCCCATATTGTATTGT  
VraSR-R GGCTTCAACTCATGGGCTTTGGCAA  
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mprF-F GGTGGCTTTATTGGTGCAGGCG  
mprF-R GATGCATCGAAAACATGGAA  











16S-F TCCGGAATTATTGGGCGTAA  
16S-R CCACTTTCCTCTTCTGCACTCA  
  800 
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Table 2. Minimal inhibitory concentrations (MICs) of DAPR CB1634 and mprF-derivatives for 801 





CB1634 4 0.5 
CB1634〉mprF 0.25 32 
CB1634〉mprF+mprF(WT) 0.75 32 
CB1634〉mprF+mprF(L826F) 3 1  on N
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No DAP + DAP No DAP + DAP A B 
Fig 1. Daptomycin effects on cytoplamic membrane and cell wall. DAPS CB1631 and 
DAPR CB1634 strains were grown in TSB (±DAP) at 37 ˚C to late exponential 
phase (2.5 hours) and labelled for 5 minutes with FM1-43FX (membrane; A) or  
HADA (peptidoglycan insertion; B). A Nikon inverted epifluorescence microscope 
was used. Exposure and contrast settings were optimized per image, i.e. 
































Fig. 2. Fluorescence microscopy analysis of: A) DAPR-CB1634 strain grown ± sublethal 
concentrations of DAP/OXA (1/2 MIC), followed by labelling with BodipyFL-VAN, fixation, 
and after mounting on slides, imaged using Deltavision microscope. B) DAPR-CB1634- 










































Fig. 3. PBPs analysis in CB1634 cells undergoing treatment with OXA, DAP 
and DAP/OXA. Detection of penicillin binding proteins PBP1, PBP2, PBP3 and 
PBP4 in membrane preparations obtained from CB1634 cells untreated and 
treated with OXA (0.5 µg/ml), DAP (1µg /ml) and DAP /OXA (0.5 µg/ml /1 µg/ml). 
Equal amounts (20 たg) of Bocillin-FL labelled membrane proteins were separated 
on 10% SDS-Page gel. Fluorescently labelled PBPs are indicated by arrows. 
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Fig. 4. A) Western blot analysis of PBP2A protein in membrane and extracellular protein 
extracts  from DAPR-CB1634 grown without (C = control) or with DAP, OXA or DAP/OXA 
combination. B) RT-PCR analysis showing mecA gene expression in DAPR-CB1634 grown 
without or with DAP, OXA or DAP/OXA combination; *: significantly higher than CB1634 control 
(no antibiotic), p< 0.05; # significantly higher than cells exposed to DAP or OXA alone, p< 
0.005. C) Western blot analysis of PBP2A protein in membrane protein extracts from 
CB1643〉mprF (MAR17), CB1634〉mprF+mprF(WT)(MAR18) and 























































































































CB1634 + DAP/OXA 
B1634 
Fig. 5. A) Effect of DAP/OXA combination on peptidoglycan crosslinking. Peptidoglycan 
muropeptide composition was analyzed by reverse phase HPLC from DAPR-CB1634 strains 
grown without or with DAP/OXA combination. Numbers 17-22 denoted highly cross-linked 
































Fig. 5.. B) Effect of mprF deletion on peptidoglycan crosslinking in the presence of OXA 
or DAP/OXA combination. Peptidoglycan muropeptide composition was analyzed by reverse 
phase HPLC from DAPR-CB1634 and DAPS-CB1634〉mprF strains grown without or with OXA 

































Fig 6. Effect of mprF mutations on PrsA membrane localization.  (A) Western blot analysis 
of PrsA protein in membrane protein extracts (upper panel) and extracellular protein extracts 
(lower panel) from DAPS-CB1631, DAPR-CB1634, CB1643〉mprF, CB1634〉mprF+mprF(WT) 
and CB1634〉mprF+mprF(L826F) grown without antibiotics. Carbonic anhydrase was used a 
loading control. (B) Western blot analysis of PBP2a and PrsA in membrane extracts prepared 
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Fig 7. Homogeneous DAPR MRSA strains do not display the see-saw effect without DAP 
induction. DAPR strain CB5014 grown overnight (O/N) in the absence (A) and in the presence (B, 
CB5014indD) of sublethal concentrations of DAP (½ MIC; 2µg/ml 50 mg/L Ca2), after which the 
adjusted inoculum was plated onto MH agar containing ½ MICs DAP (2 µg/ml). OXA E-test strips 
were placed on the plates, and incubated for 24 h. (C) western blot analysis of PBP2a present in cell 
membrane extracts collected from cells as described in (A). (D) Quantitation of mecA mRNA by real-
time RT-PCR using RNA prepared from CB5014 and CB5014IndD; relative fold changes are shown; 
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+vraSR A B 
Fig 8 
Fig 8. VraSR and DAP-mediated see-saw effect. (A) CB5013+vraSR and 
CB1631+vraSR  strains were grown O/N after which the adjusted inoculum was plated 
onto MH agar and OXA Etest strips were placed on the plates, and incubated at 37°C for 
24 h. (B) western blot analysis of PBP2a present in cell membrane extracts collected 
under the indicated conditions in DAPS CB5013 and CB1631, and their corresponding 
+vraSR counterparts (CB5013+vraSR and CB1631+vraSR, respectively).  
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Fig 9. Proposed model of MprF (A) or mutated MprF* (B) affecting lipoprotein PrsA 
anchorage. 1. MprF uses cytosolic lysyl tRNA to convert phosphatidyl glycerol (PG) to lysyl 
phosphatidyl glycerol (L-PG). 1b. Enhanced transferase and/or flippase activity of mutated MprF 
increases the proportion of L-PG compared to PG in the outer membraned leaflet. 2. Prelipoprotein 
PrsA is secreted  probably through Sec pathway. 3. PG is used by Lgt enzyme to lipid modify PrsA 
lipobox cysteine. 3b. Inhibition of Lgt-mediated acyl transfer to PrsA due to increased L-
PG/reduced PG amounts in the outer membrane leaflet. 4. Lipidated membrane-anchored PrsA will 
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